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Conclusions 
 
When the wild type ATCC 29213 bacterial strain was 
treated with Ciprofloxacin, the MIC value showed that 
a relatively low amount of the compound was 
sufficient to inhibit the bacterial growth, while the 
MICs for DNM-2, APR-II-231, and OP were 
significantly higher.  The opposite was found when 
the resistant NRS3 (MRSA) strain was treated with 
Ciprofloxacin, as the MIC was comparable to APR-
II-231 in the wild type strain.  DNM-2, APR-II-231, and 
OP, on the other hand, were found to have low MIC 
values, indicating that low amounts of these 
compounds were effective and sufficient in inhibiting 
bacterial growth. These results also support the idea 
that bacteria lacking the S84L mutation in DNA gyrase 
are able to develop resistance to DNM derivatives. 
We can conclude that the mutation of the serine to 
leucine or isoleucine is vital in bacteria’s sensitivity to 
DNM and its derivatives.  With this knowledge, a 
resistance/sensitization cycle can be applied to DNM 
and fluoroquinolones to optimize the sensitivity of the 
bacteria being treated with the two compounds and to 
help ensure that the bacteria will still be killed even if 
resistance emerges. 
  
Objectives 
 
•  Synthesize derivatives of DNM to optimize the 
potency and solubility of the compound 
 
•  Perform antibiotic susceptibility tests to determine 
if the derivatives of DNM are effective against 
fluoroquinolone resistant bacteria by targeting the 
resistance mechanisms of these bacteria 
 
•  Determine if wild type gram-positive bacteria that 
lack the S84L mutation in DNA gyrase and ParC 
S80F mutation in topoisomerase IV develop 
resistance to DNM derivatives 
 
 
 
 
Introduction 
  
Antibiotic resistant bacteria are becoming an 
increasing threat in medicine as the heavy selective 
pressure from clinical use continues.  The discovery 
and synthesis of new classes of antibiotics is vital to 
solving this worldwide problem. 
  
Fluoroquinolones were first introduced to treat gram-
posit ive and gram-negative infections. The 
mechanism of action for fluoroquinolones is to target 
bacterial type IIA topoisomerases.  More specifically, 
DNA gyrase is typically targeted in Gram-negative 
bacteria, while topoisomerase IV is more commonly 
targeted in Gram-positive bacteria.  Both DNA gyrase 
and topoisiomerase IV modulate levels of DNA 
supercoiling in bacteria.  Inhibition of these enzymes 
prevents bacterial DNA replication and causes 
bacterial death. The over prescription and overuse of 
fluoroquinolones has led to widespread resistance to 
the antibiotic.  Much of this resistance originates from 
point mutations in the GyrA subunit of DNA gyrase 
and the ParC subunit of topoisomerase IV.  These 
mutations in the GyrA subunit and the ParC subunit 
resu l t in a decreased b ind ing a ff in i ty o f 
fluoroquinolone to its target.  
 
A compound, deoxynybomycin (DNM), was first 
synthesized when trying to determine the structure of 
nybomycin. DNM was found to have antibacterial 
activity against a range of bacteria, including 
fluoroquinolone-resistant MRSA that contains a S84L 
mutation in the GyrA subunit of DNA gyrase. This 
activity led to further studies to explore the possibility 
of a new class of antibiotics that are able to target 
resistance mechanisms, like those present in 
fluoroquinolone resistant bacteria.   
Method 
 
A modular synthetic route was first used by Dr. Elizabeth Parkinson to access several DNM derivatives.  The 
synthesis begins with a Suzuki cross coupling of two different iodoamides that have modifications depending on the 
DNM derivative being synthesized.  This cross coupling is performed with a symmetrical aryl boronate, and results in 
both symmetrical and asymmetrical products.  The asymmetrical product is identified and separated, and a 
Buchwald-Hartwig ring closing mechanism catalyzed by palladium is performed.  The resulting diazanthracene is 
then deprotected by adding HBr, revealing a dianthracenol.  A methylene bridge is then inserted using a compound 
that will result in the desired derivative.  The synthesis of these derivatives takes 7 steps and results in an ~11% total 
yield.   
 
 
 
 
 
 
 
 
Antibiotic susceptibility for all strains of bacteria used was performed in triplicate using the microdilution broth method 
as outlined by the Clinical and Laboratory Standards Institute.  Each well had 2 µL of 50x stock solution containing 
the compounds being tested, except the live and dead control cells which had vehicle instead.  MH Broth was added 
to each well and bacteria with a concentration of 5x105 cfu/mL was added to each well except for the dead control 
cells.  Each well of the well plate had a volume of 100 µL and a concentration of 5x105 cfu/mL.  After incubation, the 
results were read on a Molecular Devices SpectraMax Plus 384 Microplate reader at λ=600nm. MIC values were 
defined by the lowest concentration to result in >90% growth inhibition.  
 
 
 
 
 
 
 
Results 
 
For the antibiotic susceptibility tests, a control strain of bacteria, ATCC 29213 (WT), was used and had no known 
resistance to any of the compounds tested.  NRS3 (MRSA), was used and has GyrA S84L and ParC S80F 
mutations, which confer resistance to a variety of fluoroquinolones, including Ciprofloxacin.  Four compounds were 
tested against these two strains of bacteria.  Ciprofloxacin was used as a control to test the effectiveness of our 
synthesized compounds in treating resistant bacterial strains.  DNM-2, APR-II-231, and OP were experimental DNM 
derivatives tested.  The structures of all 4 compounds are shown below. 
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Minimum Inhibitory Concentration of Compounds (µg/mL) 
Compound 
Bacterial Strain Ciprofloxacin DNM-2 APR-II-231 OP 
ATCC 29213 0.12 4.0 >16.0 >32.0 
NRS3 (MRSA) 16.0 0.03 0.5 0.5 
Commonly used logos 
